Background and aims Community pharmacies have a central role in the provision of opiate substitution therapy (OST) for drug misusers, offering accessible, additional health services within recovery-oriented systems of care. However, little is known about the patients receiving OST, availability and uptake of related services and associated pharmacy characteristics. We aimed to describe OST in terms of patients, pharmacies and services within the UK's largest health authority, NHS Greater Glasgow and Clyde, Scotland. Methods Patients completed semi-structured questionnaires and pharmacists provided summary statistics relating to OST provision. Results Responses from 508 patients receiving OST from 111 participating pharmacies revealed an established patient population, with 89 % (449/507) aged 30 years or above and 80 % (387/484) attending the same pharmacy for 1 year or more. Methadone was the main form of OST (96 % (487/508), with 97 % (491/504) receiving supervision. Within pharmacies, OST consumption was supervised in one of four main areas: consultation room, dispensing hatch, quiet/private area or over the counter. Location of supervision was considered suitably private by 96 % of patients. Positive staff attitudes, privacy and the provision of additional health services were key factors influencing choice of pharmacy. Additional health services were offered to 75 % of patients and included information provision (43 %), signposting to other health care providers (72 %) and a Scottish service offering free advice and medicines for minor ailments (74 %). Conclusion Patients and pharmacists have developed working relationships, enabling access to multiple services associated with health gain and harm reduction. Further development of enhanced services in community pharmacies is merited.
Introduction
Opiate substitution therapy (OST) is a successful and costeffective treatment for opioid dependence (Maas et al. 2013; Mattick et al. 2009 ). Receiving OST reduces morbidity and mortality (Kimber et al. 2010) in individuals dependent on illicit opiates. Methadone-related deaths reduced four-fold following the introduction of supervised consumption in community pharmacies in Scotland and England (Strang et al. 2010) , and supervision of OST is recommended for a minimum period of 3 months [Department of Health (England) (DOH) and the Devolved Administrations 2007; National Institute for Health and Care Excellence (NICE) 2007; Royal College of General Practicioners (RCGP) 2011]. Community pharmacies play a central role in the provision of OST, with many offering dispensing and supervised consumption within a convenient (Anstice et al. 2009; Luger et al. 2000; Mackridge et al. 2010 ) and discreet location (Mackridge et al. 2010) . Current UK prescribing guidelines recommend supervised consumption in the interest of public safety (DOH 2007) . Supervised methadone consumption was introduced over 10 years ago (Roberts et al. 1997) . Prescribers use their professional judgement to relax the requirement for daily supervision, e.g. if the home environment is suitable for safe storage and daily supervision restricts recovery.
OST is widely accepted by patients and the general public as part of community pharmacy provision (Lawrie et al. 2003 (Lawrie et al. , 2004 , and community pharmacies are viewed as important primary care providers. Within their recommendations to the Scottish Government, the Scottish Drug Strategy Delivery Commission (SDSDC) recommended the development of a national specification for pharmacy services for people who use drugs, expanding pharmacists' roles to contribute to a holistic recovery-oriented system of care (SDSDC 2013) . Many Scottish pharmacies also provide clean injecting equipment for people who inject drugs, creating an important role for the community pharmacist as a point of contact (Roberts and Hunter 2004) .
There are an estimated 59,500 illicit drug users in Scotland, of whom 31.8 % access services within NHS Greater Glasgow & Clyde (NHS GGC) (Information Services Division (ISD) 2014). It is estimated that 22,000 individuals are in receipt of methadone in Scotland (Scottish Government 2008) ; within NHS GGC, approximately 8,000 individuals are prescribed methadone and 1,000 prescribed buprenorphine/naloxone. The majority of community pharmacies (Audit Scotland 2012) and users of OST services (SDSDC 2013) are based in areas of high socio-economic deprivation. Almost 80 % of community pharmacies provide supervision of OST and engage with patients receiving OST on a daily basis (Scottish Government 2008) .
Previous research has focused on the practice and attitude of community pharmacists and prescribers and the experience of patients in relation to OST dispensing and supervision, predominantly methadone (Table 1) . Given the lack of contemporary information about the patients receiving and pharmacies providing OST and related services, together with the need for better evidence to inform continuous quality improvement (Bloor 2007; Scottish Government 2008 ; SDSDC 2013), we sought to characterise patients, pharmacies and services in terms of OST in the UK's largest health board, Greater Glasgow and Clyde.
Methods
Greater Glasgow and Clyde is located in the West of Scotland and covers a population of 1.1 million. Two hundred ninetytwo community pharmacies (for-profit organisations contracted to act on behalf of the NHS in relation to specified services, e.g. OST provision, prescription dispensing and advice) were invited to participate. One hundred eleven (38 %) pharmacies agreed. Ethical approval was not required.
Development of questionnaire
A semi-structured patient questionnaire (Appendix 1) was developed by AL and CH, then reviewed for face and content validity before inviting comment from a group of 15 patients who were receiving OST. The final version consisted of 27 questions pertaining to demographics; arrangements for OST provision in the pharmacy; information, advice and signposting; relationships with pharmacy staff; and overall service provision (Appendix 1).
Distribution and analysis of the questionnaire
Questionnaires were disseminated during September to November 2010. In each pharmacy, staff were asked to distribute questionnaires to patients receiving OST. All questionnaire responses were anonymised.
Completed questionnaires were entered onto an Excel spreadsheet (Microsoft Office 2007), cross checked for accuracy and completeness, and analysed using basic descriptive statistics.
Results
Thirty (27 %) pharmacies returned between 1-3 questionnaires; 65 (58 %) returned 4-6 and 16 (15 %) returned 7-10 questionnaires. Respondents' demographic details were comparable with all patients receiving OST in NHS GGC in terms of gender (66 % male respondents vs. 68 % male within NHS GGC) and age group (85.1 % of respondents 30-49 years vs. 81.2 % in NHS GGC).
Pharmacy characteristics
The characteristics of participating community pharmacies are given in Table 2 . Reflecting the NHS GGC locality, 87 % of pharmacies served large urban areas. Pharmacy ownership suggested a diverse range of all possible categories: part of a large multiple chain (40 %), independently owned (39 %), small multiple (16 %) or based within a health centre (5 %). The majority (77 %) of participating pharmacies were located in Scotland's most socioeconomically deprived areas.
Approximately one quarter of pharmacies were providers of injecting equipment, e.g. needles, syringes and other paraphernalia. Over half (56 %) of pharmacies provided OST to more than 30 patients, including 21 % who supplied OST for over 60 patients. Methadone constituted the main form of OST supplied in pharmacies (Table 2 ). All pharmacies offered a supervised consumption service for methadone and alternative OST. Table 3 provides patients' summary characteristics, classified by type of OST (methadone or alternative OST). Of 508 patients, 483 (95 %) received methadone only and 4 (0.8 %) received concomitant disulfiram (for maintenance of alcohol abstinence). Twenty-one patients (4 %) received alternative OST [buprenorphine or combined buprenorphine/naloxone (Suboxone®)] and are described separately. The majority of patients receiving methadone (53 %) were in the 30-39-year age band while over one third were 40 years or older. Most patients receiving alternative OST were 40-49 years old. For each type of OST, the male:female ratio was 2:1. Within each OST category, the majority of patients (87 % methadone, 76 % alternative OST) lived in rented accommodations. Similar proportions of patients were homeless or roofless (total 6 %) as owned their own property (total 7 %).
Patient characteristics
While most patients had attended the same pharmacy for less than 6 years, a substantial minority (94/508; 18 %) had attended the same pharmacy for over 7 years.
Treatment and supervision arrangements
Treatment and supervision arrangements are described in Table 4 . The majority (97 %) of patients received supervised OST; in most cases, pharmacies supervised on 5 or more days per week. The location of supervision in pharmacies varied, with the greatest proportion (42 %) supervised in a private consultation room. Other arrangements included the use of a dispensing hatch (27 %) and a quiet/private area (21 %). The perceived suitability of each location varied, with 206/207 (99.5 %) of those using consultation rooms disclosing that they felt the room was suitably private, while 30/34 (88 %) of those who consumed their OST at the open counter regarded this arrangement as suitable.
Approximately half of respondents declared that their pharmacies had restrictions on OST supervision or collection times. Eighty per cent of participants receiving methadone and 95 % of those receiving alternative OST reported that they waited for 5 min or less.
Reasons for choosing a pharmacy for OST
Receiving health care advice was highly ranked (Figure 1 ) as an important factor in choosing a pharmacy: 36 % of participants stated that it was a factor in their decision, although it was perceived to be less important than staff attitude (82 %), privacy (71 %), proximity to home (67 %) and waiting times (59 %).
Additional services
Additional health information was reportedly received by 75 % of patients (Table 5 ). Information provision extended to a wide range of related topics: safe storage of medicine in the home (43 %), role of medicine (24 %), overdose risk (22 %), anthrax (20 %), hepatitis (20 %) and alcohol (19 %). Verbal exchange of information was the most commonly preferred method (64 % of patients).
Other services that were utilised included: purchase of over-the-counter medicine (51 %), prescription collection service (30 %) and a needle exchange service (26 %). Most participants were aware of the Minor Ailment Service (MAS: a free service enabling community pharmacists to advise, supply products free of charge or refer patients and their families presenting with minor health concerns), with almost three-quarters (74 %) registered with their community pharmacy for the MAS in addition to their OST provision.
Seventy-two per cent of patients reported having been signposted to attend other health care services.
Relationship with pharmacy staff
Relationships with pharmacists and dispensing staff were positive (Table 6) , with over 70 % of patients reporting Bexcellentr elations with pharmacists, pharmacy staff and counter assistants. 
Discussion Principal findings
Our results indicate that pharmacies with a range of ownership categories, located in areas of deprivation, supervise a full range of opiate substitution therapies. Patients receiving OST access a variety of associated services and wider health improvement interventions through their community pharmacy. Community pharmacies, more than half of which supervise supplies for over 30 patients per day, 6 or 7 days per week, had long-standing relationships with the same patients for prolonged spells of recovery, sometimes lasting more than 10 years. This context offers an encouraging, stable and supportive environment in which individual OST patients may find it easier to recover from substance misuse. While we did not design the study to test for statistically significant differences, patients receiving alternative OST appeared to be older than those receiving methadone. It is possible that this may reflect the fact that buprenorphine-containing products are a newer treatment option and patients who have been previously prescribed methadone may have switched following treatment failure with methadone. Patients were predominately receiving methadone, which has been available as an OST for a longer period of time. If our sample can be considered representative, our results show, for the first time, an older population of patients in recovery for a longer period of time, using the same community pharmacy. This finding, together with developments in pharmacist-independent prescribing, provides a platform for additional clinical service provision aiming to retain patients in treatment and maximise recovery.
Arrangements for consumption of OST were reported as suitable, even within the small group of patients who used the open counter, in full visibility of other customers and staff. Restrictions in the times of supply were not found to be problematic. This is potentially linked to the positive reports that patients had relatively short waiting times within the pharmacy.
Appraisal of methods
We involved a larger number of pharmacies and patients than previous work. As pharmacies in Glasgow were the first to provide supervised OST, this may have led to relatively earlier innovation and service expansion than occurred in other health localities. Pharmacists and patients were self-selecting, which may limit the generalisability of our findings. Given the requirement for patients to return responses to pharmacy staff, respondents may have been more likely to have favourable views on , raising the possibility that those who were less able to read, understand and respond may have been less likely to participate. Eighty-seven per cent of our participating pharmacies were located in large urban areas (defined as settlements of over 125,000 people), with the remainder located in other urban areas or accessible small towns (ISD 2010). While we did not analyse our data by pharmacy location, our findings, while applicable to urban areas and accessible small towns, may be generalisable to rural areas, where attitudes of pharmacists towards drug misusers and service provision are not significantly different (Matheson et al. 2007 ). Further work is required to test whether these or other potential explanatory variables, e.g. patient demographics, independently predict retention in OST or other outcomes of interest. We did not collect Missing data: a n = 4 methadone; b n = 14 methadone; c n =1 alternative OST; f n = 8 methadone; g n = 3 methadone; h n = 19 methadone; i n = 1 alternative OST; j n = 2 methadone; k n = 7 methadone; l n = 2 alternative OST data on prescribing of psychotropic drugs or other comorbidities, which limits a broader understanding of the typology of the patients included.
Comparison with previous work
There are reports of higher rates of drug-related deaths associated with lower rates of supervision (Bloor 2007; Seymour et al. 2003; Strang et al. 2010 ). We found a higher rate of supervised supply for both methadone (98 %) and alternative OST (95 %) than in previous studies of pharmacist-reported supervision (Matheson et al. 2007 ). The higher rates of supervision are due to local prescribing guidance within the integrated addiction services in NHS GGC. In NHS GGC, 96 % of community pharmacies offer the opportunity to dispense and supervise OST as part of a commitment to patient care and harm reduction strategies, thereby ensuring that there is availablility of places for community pharmacy-based OST. In addition, it would appear that patients are accepting of high levels of supervision. Supervision is perhaps more acceptable when other factors, such as the attitude of pharmacy staff or availability of a suitably private area to consume OST, are perceived favourably by patients. Patients consuming methadone in highly visible areas are known to feel embarrassed by exposure to other customers and pharmacy staff (Anstice et al. 2009; Bloor 2007; Luger et al. 2000) . Given that 12 % of those consuming OST over the counter found the arrangement unsuitable, yet persisted with this arrangement, it is possible that the advantages of using their chosen pharmacy, e.g. short waiting times or positive staff attitudes, outweighed any disadvantages. If this is the case, our findings uncover features that could be the focus of quality improvement for pharmacy and other services involved in OST.
Some pharmacies have restrictions on the times when patients receiving OST can attend, usually in an attempt to structure workflow amidst other competing priorities. From a patient's perspective, these restrictions may seem inflexible and hamper efforts to return to or establish employment, education and family life (Bloor 2007 ). We report that most patients acknowledged minor restrictions, but by design, we did not explore the impact or importance of this finding. However, we ascertained that the vast majority of patients waited less than 6 min for their OST, which is important to patients (Deering et al. 2011) .
Addressing the wider health care needs of people receiving OST is challenging. OST is one aspect of harm reduction and should be set within the context of a recovery programme involving multiple services from health and social care. Pharmacy-based services for patients receiving OST are an important component of recovery services. The high reported uptake of additional and associated services is noteworthy in a population where provision has been historically low (Matheson et al. 1999) . Our findings may indicate a shift over time in pharmacy OST provision, from initial low levels of provision, through increased awareness of opportunities for health improvement (Mackridge et al. 2010) , to recommendations for the provision of associated pharmaceutical services (SDSDC 2013) in parallel with recovery-focused treatment (Scottish Government 2008) . There is evidence from repeated surveys of positive trends in pharmacists' attitudes over time towards providing services to people using drugs (Chief Scientist Office (CSO) 2014). In demonstrating provision and utilisation of pharmacy-based health promotion and harm reduction activities on a wide scale, our results suggest that pharmacists may have translated improved attitudes into improved practice. This is encouraging, given the emphasis that patients place on staff attitudes. The positive relationships observed between pharmacist and patient may be relevant to both the offering (Luger et al. 2000) and the accessing of additional services (Matheson et al. 2007 ) and, we would expect, to recovery more broadly. Missing data: a n = 13 methadone; d n = 10 methadone; e n = 20 methadone; f n = 1 alternative OST
Clinical and scientific implications
These findings extend our understanding of the positive contribution pharmacists are making to various aspects of health care for patients receiving OST. Given the length and strength of the pharmacist-patient relationship, there is an obvious platform for the introduction of additional targeted services by pharmacists for this patient group. There is an increased prevalence of older drug users within Scotland and, as this population ages, there will be challenges in relation to managing multiple medications and drug-related or other morbidities. Drug-related deaths among older drug users are more prevalent, and the number of hospital admissions for this patient population increases because of medical and psychiatric morbidities (Information Services Division 2015). Older drug users generally tend to have poorer physical and mental health [Roe 2010; Roe et al. 2010; Scottish Drugs Forum (SDF) 2009]. Therapeutic relationships should foster greater engagement with other health services and health interventions. Community pharmacies could be involved in overdose awareness and naloxone supply (Green et al. 2015; Scottish Government 2014) , blood-borne virus testing (Scottish Government 2011) and supply of direct-acting anti-viral hepatitis C treatment as well as providing services to manage long-term medical conditions such as the Chronic Medication Service (CMS) in Scotland (Scottish Government 2009 ). While our descriptive study, by design, did not seek to examine the impact of pharmacy-based OST on dimensions such as social adjustment, health improvement or criminal behaviour, other available evidence indicates a positive impact of treatment retention on these outcomes (Palmateer et al. 2014; Scottish Government Social Research 2009) .
Further work
This study has indicated the extent of provision and uptake of pharmacist-led activities for patients receiving OST and can be used as a platform to test more advanced services in this population, e.g. blood-borne virus testing and independent prescribing, as part of a collaborative approach to an ageing population of drug users. Longitudinal follow-up in the context of experimental or analytical studies is needed to examine whether pharmacy service delivery promotes retention in treatment and whether it makes an independent contribution to improving health outcomes, e.g. prevention of blood-borne diseases, social adjustment or minimising criminal behaviour. Future work could include health service contacts and consider the cost effectiveness of pharmacy-based OST services in this context.
Conclusions
Urban patients receiving OST in NHS Greater Glasgow and Clyde access a wide range of services offered by community pharmacies in relation to both addiction-specific interventions and general health interventions. Patient and pharmacy characteristics point to the need and potential for further role expansion for community pharmacies. The long-standing and positive relationships between patients and pharmacy staff are of particular importance within the context of an ageing population of drug users engaging in daily treatment in pharmacies.
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Appendix 1 OST patient questionnaire This questionnaire relates to the community pharmacy services offered to patients receiving either Methadone, Suboxone, Subutex or Disulfiram from a community pharmacy. Your views on this service are important and will support us to improve and develop the service. Thank you very much for completing this questionnaire, it should only take five to ten minutes to complete. The information is confidential and completely anonymous. All data will be used in accordance with the Data Protection Act 1998. 
